Last Updated : September 13, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0049-000
Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of tocilizumab for the treatment of COVID-19. We also characterized which hospitalized patients are most likely to benefit from treatment with tocilizumab.
Tocilizumab may be efficacious in reducing the length of hospitalization and the progression to the combined end point of mechanical ventilation or death. Treatment with tocilizumab in patients matching the characteristics of the patient populations in the RECOVERY and REMAP-CAP (2 of the largest and best-run) trials may yield the best outcomes. Evidence is lacking for patients with a compromised immune system, comorbidities, and concomitant bacterial infections.
Files
Last Updated : September 13, 2023